Investigational Drug Information for GB1211
✉ Email this page to a colleague
What is the drug development status for GB1211?
GB1211 is an investigational drug.
There have been 5 clinical trials for GB1211.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2021.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, and Fibrosis. The leading clinical trial sponsors are Galecto Biotech AB, Linical Europe GmbH, and QPS Holdings LLC.
Summary for GB1211
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-03-01) |
| Vendors | 6 |
Recent Clinical Trials for GB1211
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Compare Pharmacokinetics of GB1211 | QPS Holdings LLC | Phase 1 |
| A Study to Compare Pharmacokinetics of GB1211 | Galecto Biotech AB | Phase 1 |
| A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | Hoffmann-La Roche | Phase 1/Phase 2 |
Clinical Trial Summary for GB1211
Top disease conditions for GB1211
Top clinical trial sponsors for GB1211
US Patents for GB1211
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
